Oncology clinics of the future may be organised by tumour biomarker signature rather than by disease, a specialist meeting in Sydney has heard. With novel selectively-targeted tyrosine kinase inhibitors (TKIs) likely to become available from next year, it may make more sense to have solid tumours treated according to their molecular susceptibility than by anatomical ...
Lung cancer: personalised medicine to be delivered by ‘molecular champions’
By Michael Woodhead
30 Jul 2019